List of Excipients in API neostigmine methylsulfate and glycopyrrolate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing neostigmine methylsulfate and glycopyrrolate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Endo USA | PREVDUO | neostigmine methylsulfate and glycopyrrolate | 42023-269 | EDETATE DISODIUM | 2038-10-25 |
| Endo USA | PREVDUO | neostigmine methylsulfate and glycopyrrolate | 42023-269 | HYDROCHLORIC ACID | 2038-10-25 |
| Endo USA | PREVDUO | neostigmine methylsulfate and glycopyrrolate | 42023-269 | NITROGEN | 2038-10-25 |
| Endo USA | PREVDUO | neostigmine methylsulfate and glycopyrrolate | 42023-269 | SODIUM CHLORIDE | 2038-10-25 |
| Endo USA | PREVDUO | neostigmine methylsulfate and glycopyrrolate | 42023-269 | SODIUM HYDROXIDE | 2038-10-25 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for neostigmine methylsulfate and glycopyrrolate
Excipient focus: EDETATE DISODIUM
neostigmine methylsulfate and glycopyrrolate drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
neostigmine methylsulfate and glycopyrrolate drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: NITROGEN
neostigmine methylsulfate and glycopyrrolate drug variants containing NITROGEN
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing NITROGEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
neostigmine methylsulfate and glycopyrrolate drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
neostigmine methylsulfate and glycopyrrolate drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
neostigmine methylsulfate and glycopyrrolate drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Endo USA | neostigmine methylsulfate and glycopyrrolate | 42023-269 |
| >Company | >Ingredient | >NDC |
neostigmine methylsulfate and glycopyrrolate drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch